MedTrace Logo

Hybrid Closed Loop System for Patients on Multiple Daily Insulin Injections

NCT04145804 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-21

No results posted yet for this study

Summary

The objective of this study is to assess structured group education onboarding protocol of the 670 G Hybrid Closed Loop (HCL) systems in achieving glucose control of patients on Multiple Daily Insulin Injections (MDI).

Conditions

Interventions

DEVICE

Medtronic Minimed 670G insulin pump

It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.

Sponsors & Collaborators

  • Sidra Medicine

    collaborator OTHER

  • Hamad Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Dabia Al Mohanadi, MD, FRCPC · Hamad Medical Corporation

  • Goran Petrovski, MD, PhD · Sidra Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-07-31
Completion
2022-01-31

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04145804 on ClinicalTrials.gov